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Abstract
Background: The short consultation length in primary care is a source of concern, and the wish for more consultation
time is a common reason for patients to seek complementary medicine. Physicians practicing anthroposophic medicine
have prolonged consultations with their patients, taking an extended history, addressing constitutional, psychosocial, and
biographic aspect of patients' illness, and selecting optimal therapy. In Germany, health benefit programs have included
the reimbursement of this additional physician time. The purpose of this study was to describe clinical outcomes in
patients with chronic diseases treated by anthroposophic physicians after an initial prolonged consultation.
Methods: In conjunction with a health benefit program in Germany, 233 outpatients aged 1–74 years, treated by 72
anthroposophic physicians after a consultation of at least 30 min participated in a prospective cohort study. Main
outcomes were disease severity (Disease and Symptom Scores, physicians' and patients' assessment on numerical rating
scales 0–10) and quality of life (adults: SF-36, children aged 8–16: KINDL, children 1–7: KITA). Disease Score was
documented after 0, 6 and 12 months, other outcomes after 0, 3, 6, 12, 18, 24, and (Symptom Score and SF-36) 48
months.
Results:  Most common indications were mental disorders (17.6% of patients; primarily depression and fatigue),
respiratory diseases (15.5%), and musculoskeletal diseases (11.6%). Median disease duration at baseline was 3.0 years
(interquartile range 0.5–9.8 years). The consultation leading to study enrolment lasted 30–60 min in 51.5% (120/233) of
patients and > 60 min in 48.5%. During the following year, patients had a median of 3.0 (interquartile range 1.0–7.0)
prolonged consultations with their anthroposophic physicians, 86.1% (167/194) of patients used anthroposophic
medication.
All outcomes except KITA Daily Life subscale and KINDL showed significant improvement between baseline and all
subsequent follow-ups. Improvements from baseline to 12 months were: Disease Score from mean (standard deviation)
5.95 (1.74) to 2.31 (2.29) (p < 0.001), Symptom Score from 5.74 (1.81) to 3.04 (2.16) (p < 0.001), SF-36 Physical
Component Summary from 44.01 (10.92) to 47.99 (10.43) (p < 0.001), SF-36 Mental Component Summary from 42.34
(11.98) to 46.84 (10.47) (p < 0.001), and KITA Psychosoma subscale from 62.23 (19.76) to 76.44 (13.62) (p = 0.001). All
these improvements were maintained until the last follow-up. Improvements were similar in patients not using diagnosis-
related adjunctive therapies within the first six study months.
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Conclusion:  Patients treated by anthroposophic physicians after an initial prolonged consultation had long-term
reduction of chronic disease symptoms and improvement of quality of life. Although the pre-post design of the present
study does not allow for conclusions about comparative effectiveness, study findings suggest that physician-provided
anthroposophic therapy may play a beneficial role in the long-term care of patients with chronic diseases.
Background
The short consultation length in primary care (average
7½–15½ min in seven European countries [1,2]) is a
long-standing source of concern [3,4]. Physicians who
have short consultations give less lifestyle advice and have
less satisfied patients, but it is not clear if the amount of
time spent is the causative factor or a marker for other
attributes [4]. In intervention studies to increase consulta-
tion length, the average duration was increased by only 1–
3 minutes, patient satisfaction was not improved, and
effects on patients' health were not evaluated [5].
Whereas sufficient time with the physician is a high prior-
ity for primary care patients [6], the wish for more consul-
tation time is also a common reason for patients to seek
complementary medicine [7]. Some complementary ther-
apies are provided by primary care physicians, and these
physicians have prolonged consultations, providing ther-
apies such as acupuncture, homeopathy, or anthropo-
sophic medicine (AM).
AM is a complementary system of medicine founded by
Rudolf Steiner and Ita Wegman [8], provided by physi-
cians and non-medical practitioners. AM acknowledges a
spiritual-existential dimension in man which is assumed
to interact with psychological and somatic levels in health
and disease. AM therapy for chronic disease aims to coun-
teract constitutional vulnerability, stimulate salutogenetic
self-healing capacities, and strengthen patient autonomy
[9-11]. This is sought to be achieved by counselling [10],
by non-verbal artistic therapies using painting or clay
[12,13], music [14] or speech exercises [15], by eurythmy
movement exercises [16], by physical therapies [17,18],
and by special medication. A key concept of AM medica-
tion therapy is typological correspondences between
pathophysiological processes in man and formative forces
working in minerals, plants and animals, reflecting a com-
mon evolution of man and nature [8-11]. These corre-
spondences are used therapeutically in medications of
mineral, botanical or zoological origin. The manufactur-
ing of AM medication includes special pharmaceutical
processes which are rarely used for non-AM medication:
e.g. the production of metal mirrors by chemical vapour
decomposition, and the processing of herbs by fermenta-
tion, toasting, carbonising, incineration or digestion (heat
treatment at 37°C). AM medications can be prepared in
concentrated form or in homoeopathic potencies, and are
administered in various ways (oral, rectal, vaginal, con-
junctival, nasal or percutaneous application, or by subcu-
taneous, intracutaneous or intravenous injection).
Currently, more than 2000 different AM medications are
on the market [19,20].
Certification as an AM physician requires a completed
medical degree and a structured postgraduate AM training
according to international criteria [21]. In Europe, more
than 2000 AM physicians provide comprehensive AM
therapy in inpatient and outpatient settings [21]. World-
wide, AM physicians work in 56 countries [22].
AM physicians have prolonged consultations with their
patients. These consultations are used to take an extended
history, to address constitutional, psychosocial, and bio-
graphic-existential aspect of patients' illness, to explore
the patient's preparedness to engage in treatment, and to
select optimal therapy for each patient [9,10,23]. The
importance of addressing psychosocial and biographic
aspects of illness is also recognised in conventional medi-
cine [24], and in this respect AM practice has been studied
as a possible model of integrated primary care [10].
In Germany, several health benefit programs ("Modell-
vorhaben") have included the reimbursement of addi-
tional time spent by physicians providing complementary
therapies [25-27]. We here present a study of patients
treated by AM physicians after an initial AM-related con-
sultation of at least 30 minutes duration.
Methods
Study design and objective
This is a prospective four-year cohort study in a real-world
medical setting. The study was part of a research project
on the effectiveness and costs of AM therapies in outpa-
tients with chronic disease (Anthroposophic Medicine
Outcomes Study, AMOS) [26,28]. The AMOS project was
initiated by a health insurance company in conjunction
with a health benefit program. The primary research ques-
tion of the present study was: Is physician-provided AM
therapy after an initial prolonged AM-related consultation
associated with clinically relevant improvement of symp-
toms? Further research questions concerned quality of
life, use of adjunctive therapies and health services,
adverse reactions, and therapy satisfaction.BMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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Setting, participants, and therapy
All physicians certified by the Physicians' Association for
Anthroposophical Medicine in Germany and working in
an office-based practice or outpatient clinic in Germany
were invited to participate in the study. The participating
physicians were instructed to enrol consecutive patients
fulfilling eligibility criteria. Inclusion criteria were (1) out-
patients aged 1–75 years, (2) an initial AM-related consul-
tation  ≥ 30 min with the study physician for any
indication (main diagnosis). Exclusion criteria were previ-
ous AM-related consultation ≥30 min for the main diag-
nosis. Patients were treated according to the physicians'
discretion. Therapies were classified as: physician-pro-
vided AM therapy (AMT: AM-related consultations with
study physicians, AM medication), AM adjunctive therapy
(AM art therapy, eurythmy therapy), non-AM adjunctive
therapy (all other therapies).
Clinical outcomes
￿ Disease severity was assessed on numerical rating scales
[29] from 0 („not present“) to 10 („worst possible“): Dis-
ease Score (physician's global assessment of severity of
main diagnosis, documented in patients enrolled up to 30
Sep 2000); Symptom Score (patients' assessment of one to
six most relevant symptoms present at baseline, docu-
mented in patients enrolled after 1 Jan 1999).
￿ Quality of life was assessed with SF-36® Physical and
Mental Component Summary Measures, the eight SF-36
subscales, and the SF-36 Health Change item [30] for
adults; with KINDL® 40-item version, Summary Score and
four subscales [31] for children 8–16 years; and with KITA
Psychosoma and Daily Life subscales [32] for children 1–
7 years.
Disease Score was documented after 0, 6 and 12 months,
other clinical outcomes after 0, 3, 6, 12, 18, 24, and
(Symptom Score and SF-36) 48 months.
Other outcomes
￿ Adjunctive therapy and health service use in the pre-
study year was documented at study enrolment, use in the
first study year was documented after six and 12 months,
and use in the second study year was documented after 18
and 24 months. Items were: medication (additional doc-
umentation after three months), physician and dentist
visits, paraclinical investigations, inpatient hospital and
rehabilitation treatment, surgeries, physiotherapy, ergot-
herapy, psychotherapy, Heilpraktiker (non-medical prac-
titioner) visits, and sick leave.
￿ Use of diagnosis-related non-AM adjunctive therapies
within the first six study months was analysed in patients
with a main diagnosis of mental, respiratory or muscu-
loskeletal diseases, or headache syndromes. Diagnosis-
related therapies were any of the following therapies, if
used for at least one day per month: Mental diseases: psy-
chotherapy (in children ergotherapy or play therapy),
antiepileptic, psycholeptic, analeptic, and anti-addiction
drugs (ATC-Index N03A, N05-06, N07B); Respiratory dis-
eases: relevant drugs (H02, J01-02, J04-05, J07A, L03,
R01, R03, R06-07) or surgery; Musculoskeletal diseases:
immunosuppressive, musculoskeletal, analgesic and anti-
depressant drugs (L04, M01-05, M09, N02A-B, N06A),
physiotherapy or relevant surgery; Headache disorders:
analgesics, antimigraine drugs and antidepressants
(C04AX01, C07AA05, C07AB02, C08CA06, C08DA01,
N02, N03AG01, N06A, N07CA03).
￿ Therapy ratings were documented after six and 12
months: Patient rating of therapy outcome, patient satis-
faction with therapy, therapy effectiveness rating by
patient and physician.
￿ Adverse drug or therapy reactions were documented dur-
ing the first 24 study months: cause, intensity (mild/mod-
erate/severe = no/some/complete impairment of normal
daily activities); Serious Adverse Events (physician docu-
mentation).
Data collection
All data were documented with questionnaires sent in
sealed envelopes to the study office. Physicians docu-
mented eligibility criteria; all other items were docu-
mented by patients (by caregivers of children < 17 years)
unless otherwise stated. Patient responses were not made
available to physicians. Physicians were compensated €
40 per included and fully documented patient, while
patients received no compensation.
Data were entered twice by two different persons into
Microsoft® Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University Berlin,
and was conducted according to the Helsinki Declaration
and the International Conference on Harmonisation
Good Clinical Practice guidelines. Written informed con-
sent was obtained from all patients before enrolment.
Data analysis
Data analysis (SPSS®  13.0.1, StatXact®  5.0.3) was per-
formed on all patients fulfilling eligibility criteria. For
continuous data the Wilcoxon Signed-Rank test was used
for paired samples and the Mann-Whitney U-test for inde-
pendent samples; median differences with 95% confi-
dence intervals (95%-CI) were estimated according to
Hodges and Lehmann [33]. For binominal data McNemarBMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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test and Fisher's exact test were used. All tests were two-
tailed. Significance criteria were p < 0.05 and 95%-CI not
including 0. Pre-post effect sizes were calculated as Stand-
ardised Response Mean (= mean change score divided by
the standard deviation of the change score) and classified
as small (0.20–0.49), medium (0.50–0.79), and large
(≥0.80) [34]. Unless otherwise stated, therapies and
health services were analysed in patients enrolled after 1
Jan 1999 with at least three out of five follow-ups availa-
ble; for each item and follow-up period, missing values
were replaced by the group mean value. Clinical outcomes
were analysed in patients with evaluable data for each fol-
low-up, without replacement of missing values.
Results
Participating physicians
78 physicians screened patients. 72 physicians enrolled
patients into the study; these physicians did not differ sig-
nificantly from all certified AM physicians in Germany (n
= 362) regarding gender (59.7% vs. 62.2% males), age
(mean 45.4 vs. 47.5 years), number of years in practice
(17.5 vs. 19.5), or the proportion of primary care physi-
cians (80.6% vs. 85.0%).
Patient recruitment and follow-up
From 1 July 1998 to 31 March 2001, a total of 260
patients were screened for inclusion. 233 patients fulfilled
all eligibility criteria and were included in the study (Fig-
ure 1). Of the 233 included patients, 13 patients were also
included in a study of depression [35], and one patient
was included in a study of low back pain [36]. The last
patient follow-up ensued on 27 March 2005. Included
and not included patients did not differ significantly
regarding age, gender, diagnosis, disease duration, base-
line Disease Score, or baseline Symptom Score.
73.8% (172/233) of patients were enrolled by general
practitioners, 9.4% by paediatricians, 4.7% by internists,
and 12.0% by other specialists. The physicians' setting was
primary care practice (84.1% of patients, n = 196/233),
referral practice (9.0%), and outpatient clinic (6.9%).
98.3% (229/233) of patients returned at least one follow-
up questionnaire. The 12-month questionnaire was
returned by 89.7% of patients; these patients did not dif-
fer significantly from non-respondents (10.3%) regarding
age, gender, diagnosis, disease duration, baseline Disease
Score, or baseline Symptom Score. Corresponding drop-
out analyses for the 24-month follow-up also showed no
differences. The physician follow-up documentation was
available for 84.5% (197/233) of patients after six months
and for 81.7% after 12 months.
Baseline characteristics
Most frequent main diagnoses, classified by ICD-10
(International Classification of Diseases, Tenth Edition),
were F00-F99 Mental Disorders (17.6%, 41/233 patients)
J00-J99 Respiratory Diseases (15.5%), M00-M99 Muscu-
loskeletal Diseases (11.6%), G00-G99 Nervous System
Diseases (9.9%), and L00-L99 Skin and Subcutaneous Tis-
sue Diseases (9.0%). Most frequent single diagnoses were
depression (6.9%, 16/233 patients), headache/migraine
(5.6%), recurrent infections (3.9%), fatigue (3.4%),
asthma (3.4%), and atopic dermatitis (3.4%).
Median disease duration was 3.0 years (interquartile
range (IQR) 0.5–9.8 years, mean 34.9 years). The patients
had median 1.0 (IQR 1.0–2.0) comorbid diseases. Most
common comorbid diseases, classified by ICD-10, were
M00-M99 Musculoskeletal Diseases (17.0%, 56 of 329
diagnoses), J00-J99 Respiratory Diseases (9.7%), and F00-
F99 Mental Disorders (9.4%).
The patients were recruited from 15 of 16 German federal
states. Median age was 38.0 years (IQR 23.0–47.0, range
1.0–74.0 years, mean 34.9 years). Compared to the Ger-
man population, socio-demographic items were more
favourable for education, occupation, income, alcohol,
smoking in females, overweight, sport, and severe disabil-
ity status; items were similar for unemployment, living
alone, smoking in males, and underweight; and were less
favourable for work disability pension and sick-leave
(Table 1).
Therapies
The duration of the initial AM-related consultation lead-
ing to study enrolment was 30–45 min in 35.2% (82/233)
of patients, 45–60 min in 16.3%, and >60 min in 48.5%.
During the following year, the patients had median 3.0
(IQR 1.0–7.0) further AM-related consultations with their
study physician, thereof median 1.0 (IQR 0.0–3.0) con-
sultation ≥60 min and 0.5 (IQR 0.0–2.0) consultation
45–60 min. AM medication was used by 71.1% (138/
194) of patients during the first three months after study
enrolment, by 83.0% during the first six months, and by
86.1% during the first 12 months (analysed in patients
with complete follow-up data after 3, 6, and 12 months;
see also Table 2). During the first six study months 3.8%
(8/211) of evaluable patients had AM art therapy, and
14.2% (30/211) had eurythmy therapy.
Non-AM adjunctive therapies, health services, and sick
leave are listed in Table 2, together with AM medication.
Comparing the pre-study year to the first and second
study year, respectively, the only consistent changes over
both years were increases in AM medication use and psy-
chotherapy. In the first study year the number of physi-
cian and dentist visits increased by median 1.7 (averageBMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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Patient recruitment and follow-up Figure 1
Patient recruitment and follow-up. *18-, 24-, and 48-month follow-up questionnaires were not sent to patients enrolled 
before 1 Jan 1999.
No further questionnaires 
sent to 27 patients* 
Not included: n = 27 
x  Patients’ questionnaire missing: n = 9 
x  Patients’ and physicians’ questionnaire 
dated > 30 days apart: n = 8 
x  Patient aged < 1 or > 75 years: n = 3 
x  No informed consent: n = 3 
x  Other reasons: n = 4 
Included in study
n = 233 
Screened for inclusion 
n = 260 
6-month questionnaire 
sent to 233 patients 
Returned
n = 213 (91.4%) 
Returned
n = 221 (94.8%) 
3-month questionnaire 
sent to 233 patients 
Returned
n = 164 (79.6%) 
24-month questionnaire 
sent to 206 patients 
Returned
n = 209 (89.7%) 
12-month questionnaire 
sent to 233 patients 
Not returned 
n = 12 (4.2%) 
Not returned 
n = 20 (8.6%) 
Not returned 
n = 24 (10.3%) 
Not returned 
n = 42 (20.4%) 
Not returned 
n = 33 (16.0%) 
Returned
n = 173 (84.0%) 
18-month questionnaire 
sent to 206 patients 
Returned
n = 145 (70.4%) 
48-month questionnaire 
sent to 206 patients 
Not returned 
n = 61 (29.6%) BMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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1.4) visits; notably this number (average 16.6 in first year)
includes AM-related consultations with the study physi-
cians (average 5.2).
Use of diagnosis-related non-AM adjunctive therapies (see
Methods) within the first six study months was analysed
in patients with a main diagnosis of mental, respiratory or
musculoskeletal diseases, or headache syndromes (n =
117). Out of 103 evaluable patients, 63% (n = 65) had no
diagnosis-related adjunctive therapy.
Clinical outcomes
Disease Score (Figure 2), Symptom Score (Figure 2), all
eleven SF-36 scores (adults, Figure 3), and the KITA Psy-
chosoma subscale (children aged 1–7, Figure 4) improved
significantly between baseline and nearly all subsequent
follow-ups (75 significant and four non-significant
improvements in 79 pre-post comparisons). For all these
14 outcomes, the most pronounced improvement
occurred during the first six months. After 12-months,
Disease and Symptom Scores were improved from base-
line in 88.4% and 83.2% of patients, respectively (Table
3); an improvement of ≥50% of baseline scores was
observed in 69.0% (107/155 evaluable patients) and
48.4% (89/184), respectively. Disease and Symptom
Scores improved similarly in adults and in children. Effect
sizes for the 0–12 month comparison were large for Dis-
ease and Symptom Scores (1.52 and 1.05) and small-to-
medium (range 0.33–0.71) for the SF-36 scores and KITA
Psychosoma (Table 3). All these improvements were
maintained until the last follow-up. KINDL scores (chil-
dren aged 8–16, Figure 5) and the KITA Daily Life subscale
(children aged 1–7, Figure 4) did not change significantly
during the study (exceptions: two significant improve-
ments in 30 pre-post comparisons).
We performed three post-hoc sensitivity analyses of 0–12
month Disease and Symptom Score outcomes. The first
sensitivity analysis concerned dropout bias. The main
analysis had comprised all patients with evaluable data at
baseline and 12-month follow-up. In the first sensitivity
analysis, missing values after 12 months were replaced
with the last value carried forward, reducing the average
0–12 month Disease and Symptom Score improvements
by 15% (3.65→3.12 points) and 5% (2.69→2.56 points),
respectively. The second analysis concerned the effect of
AM adjunctive therapies: The sample was restricted to
patients using neither eurythmy nor art therapy in the first
six study months, whereby the average improvement was
increased by 4% for Disease Score (3.65→3.78) and was
virtually unchanged for Symptom Score (2.69→2.68
points). The third analysis concerned the effects of rele-
vant non-AM adjunctive therapies, and was performed on
patients with a main diagnosis of mental, respiratory or
musculoskeletal diseases or headache syndromes.
Restricting this sample to patients not using diagnosis-
Table 1: Socio-demographic data
Study patients German primary care patients
Items N Percent Percent Source
Female gender 169/233 73% 53% [45]
Age groups 0–19 years 54/233 23% 14% [45]
20–39 years 73/233 31% 27% [45]
40–59 years 87/233 37% 27% [45]
60–75 years 19/233 8% 21% [45]
Adult study patients enrolled after 1. Jan 1999 German population
"Fachhochschule" or university entrance qualification 69/157 44% 19% [46]
University degree 32/156 21% 6% [46]
Wage earners 7/157 4% 18% [46]
Unemployed during last 12 months Economically active patients 7/91 8% 10% [46]
Living alone 25/154 16% 21% [46]
Net family income < 900 € per month 15/136 11% 16% [46]
Alcohol use daily (EYT) vs. almost daily (Germany) Male 4/32 13% 28% [47]
Female 3/125 2% 11%
Regular smoking Male 14/32 44% 37% [48]
Female 18/124 15% 28%
Sports activity ≥ 1 hour weekly Age 25–69 71/141 50% 39% [49]
Body mass index < 18.5 (low) Male 0/32 0% 1% [50]
Female 6/124 5% 4%
Body mass index ≥ 25 (overweight) Male 9/32 28% 56% [50]
Female 32/124 26% 39%
Permanent work disability pension 9/157 6% 3% [51]
Severe disability status 8/157 5% 12% [52]
Sick leave days in the last 12 months, mean (SD) Economically active patients 22.4 (44.8) days 17.0 days [53]BMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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related adjunctive therapies during the first six study
months (see Methods), the average improvement was
increased by 4% for Disease Score (3.84→3.98) and was
virtually unchanged for Symptom Score (2.77→2.76
points).
Other outcomes
At six-month follow-up, patients' average therapy out-
come rating (numeric scale from 0 "no help at all" to 10
"helped very well") was 7.21 (SD 2.64); patient satisfac-
tion with therapy (from 0 "very dissatisfied" to 10 "very
satisfied") was 7.81 (2.45). Patients' therapy effectiveness
rating was positive ("very effective" or "effective") in
75.5% (157/208) of patients, and negative ("less effec-
tive", "ineffective" or "not evaluable") in 24.5%. Physi-
cians' effectiveness rating was positive in 80.9% (157/
194) and negative in 19.1%. Ratings of therapy outcome,
satisfaction and effectiveness did not differ significantly
between adults (patient rating) and children (proxy rating
by caregivers), or between six- and 12-month follow-ups.
Table 3: Clinical outcomes 0–12 months
Item N 0 months 12 months 0 months vs. 12 months
Mean (SD) Mean (SD) P-value Median difference (95%-CI)* Improved SRM
Disease Score (0–10) 155 5.95 (1.74) 2.31 (2.29) p < 0.001 4.00 (3.50 to 4.50) 88% 1.52
Symptom Score (0–10) 184 5.74 (1.81) 3.04 (2.16) p < 0.001 2.97 (2.50 to 3.25) 83% 1.05
SF-36 scales (0–100)
-Physical Function 161 77.09 (24.07) 84.41 (20.69) p < 0.001 7.50 (5.00 to 10.00) 60% 0.37
-Role Physical 157 55.47 (38.39) 72.29 (36.64) p < 0.001 25.00 (12.50 to 37.50) 46% 0.42
-Role-Emotional 157 68.15 (37.43) 81.63 (31.98) p < 0.001 33.33 (16.67 to 33.34) 39% 0.33
-Social Functioning 161 67.93 (25.07) 77.10 (23.06) p < 0.001 12.50 (6.25 to 18.75) 52% 0.34
-Mental Health 160 58.74 (18.25) 66.10 (18.34) p < 0.001 8.00 (4.00 to 10.00) 63% 0.43
-Bodily Pain 161 59.89 (27.62) 71.27 (26.76) p < 0.001 15.50 (9.50 to 21.00) 54% 0.38
-Vitality 160 42.53 (18.34) 52.84 (18.49) p < 0.001 12.50 (10.00 to 17.50) 60% 0.53
-General Health 161 53.10 (19.30) 61.01 (19.48) p < 0.001 8.50 (5.00 to 11.00) 63% 0.45
SF-36 Health Change (1–5**) 159 3.27 (1.08) 2.14 (1.02) p < 0.001 1.50 (1.00 to 2.00) 65% 0.71
SF-36 Physical Component 154 44.01 (10.92) 47.99 (10.43) p < 0.001 3.97 (2.71 to 5.30) 73% 0.42
SF-36 Mental Component 154 42.34 (11.98) 46.84 (10.47) p < 0.001 3.98 (2.30 to 5.71) 64% 0.40
KINDL subscales (0–100)
-Psychic 16 69.75 (19.91) 69.74 (21.57) p = 0.782 1.13 (-4.55 to 5.68) 56% 0.00
-Somatic 16 71.18 (17.21) 71.74 (19.88) p = 0.520 2.78 (-4.16 to 8.33) 63% 0.03
-Social 16 74.30 (14.89) 69.73 (18.78) p = 0.292 -4.16 (-9.72 to 3.65) 31% -0.26
-Function 15 67.42 (12.08) 69.18 (14.45) p = 0.367 2.04 (-3.41 to 6.82) 67% 0.20
KINDL Summary Score (0–100) 16 70.39 (17.67) 69.77 (17.91) p = 0.889 0.31 (-4.02 to 4.93) 50% -0.06
KITA subscales (0–100)
-Psychosoma 31 62.23 (19.76) 76.44 (13.62) p = 0.001 13.54 (4.17 to 21.87) 77% 0.62
-Daily Life 29 63.22 (12.40) 67.96 (15.43) p = 0.038 6.25 (0.00 to 12.50) 55% 0.28
*Positive differences indicate improvement. Improved: Percentage of patients improved from baseline. **1 = "much better now than one year ago", 
5 = "much worse now than one year ago". SRM: Standardised Response Mean effect size (small: 0.20–0.49, medium: 0.50–0.79, large: ≥ 0.80).
Table 2: AM medication, non-AM adjunctive therapies, health service use, and sick leave days
Item Pre-study year 0–12 months 12–24 months
Mean (SD) Mean (SD) Median difference (95%-
CI) from pre-study year
P value Mean (SD) Median difference (95%-
CI) from pre-study year
P value
AM medicines per day 0.29 (0.68) 0.78 80.92) 0.47 (0.36 to 0.59) p < 0.001 0.47 (0.85) 0.17 (0.09 to 0.26) p < 0.001
Non-AM medicines per day 0.69 (1.10) 0.82 (1.01) 0.12 (0.04 to 0.22) p = 0.005 0.68 (0.90) 0.04 (-0.05 to 0.15) p = 0.447
Physician and dentist visits 15.23 (15.27) 16.64 (13.53) 1.69 (0.19 to 2.99) p = 0.006 14.84 (14.35) -0.78 (-2.43 to 1.00) p = 0.698
Paraclinical investigations 5.16 (5.91) 5.85 (7.52) 0.00 (-0.50 to 1.00) p = 0.665 4.34 (5.32) -0.98 (-1.50 to -0.08) p = 0.011
Hospital days 4.68 (16.25) 1.77 (5.82) -2.50 (-8.00 to 1.00) p = 0.123 3.04 (19.92) -2.50 (-5.50 to 0.00) p = 0.046
Rehabilitation days 0.89 (5.05) 1.74 (6.75) 7.00 (0.00 to 14.48) p = 0.041 0.67 (3.43) -0.62 (-0.90 to -0.56) p = 0.008
Surgeries 0.21 (0.51) 0.17 (0.49) 0.00 (-0.50 to 0.00) p = 0.342 0.14 (0.40) -0.34 (-0.46 to 0.07) p = 0.494
Physiotherapy and ergotherapy 
sessions
9.25 (25.98) 11.28 (34.02) 1.50 (-2.50 to 6.00) p = 0.541 9.88 (25.95) 0.22 (-3.59 to 5.10) p = 0.885
Psychotherapy sessions 2.50 (8.04) 3.12 (9.06) 3.50 (0.50 to 7.42) p = 0.023 3.58 (9.88) 2.78 (1.72 to 6.52) p = 0.007
Sick leave days* 22.42 (44.79) 27.61 (71.91) 1.24 (-7.50 to 9.00) p = 0.748 26.39 (62.96) 0.50 (-7.00 to 8.18) p = 0.823
Patients with Heilpraktiker visit 
(n + %)**
21/143 (14.7%) 18/143 (12.6%) p = 0.571 22/143 (15.4%) p = 1.000
Patients enrolled after 1 Jan 1999 with at least 3 of 5 follow-ups (n = 182). *Patients engaged in economic activity (n = 80). **Patients with complete 
data for all time periods.BMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
Page 8 of 12
(page number not for citation purposes)
Disease and Symptom Scores Figure 2
Disease and Symptom Scores. Disease Score: physicians' assessment, Symptom Score: patients' assessment. Range 0 "not 
present", 10 "worst possible".
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SF-36 Physical and Mental Component Summary Measures Figure 3
SF-36 Physical and Mental Component Summary Measures. Higher scores indicate better health. Adult patients and 
German population (standardised for age and gender) [30]
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Adverse reactions to AM medication were reported in five
(2.5%) of 197 patients using AM medication at least once
during 24-month follow-up (causal relationship con-
firmed in four patients, not confirmed in one patient
[20]). The intensity of these reported reactions was mild
in one patient and moderate in four patients. Three
(1.5%) patients stopped AM medication use because of
suspected adverse reactions: Chamomilla/Malachit comp.
(burning eyes), Conchae D6 (increased anxiety), and
Oxalis 30% ointment (allergic exanthema). Adverse drug
reactions from non-AM medication were reported in
13.5% (28/207) of users; medication was stopped in
seven patients. No adverse reactions to adjunctive AM
eurythmy or art therapies occurred but six patients had
adverse reactions to non-AM non-drug therapies (surgery:
n = 2, dental treatment: n = 2, acupuncture: n = 2).
Three patients had Serious Adverse Events. One patient
died from gastric carcinoma and two were acutely hospi-
talised for thrombosis of lower extremity and Henoch-
Schönlein purpura, respectively. None of these SAE Seri-
ous Adverse Events were related to any therapy or medica-
tion.
Discussion
This prospective cohort study is the first study of compre-
hensive AMT for chronic disease performed in primary
care. We aimed to obtain information on AMT under rou-
tine conditions in Germany and studied clinical outcomes
in outpatients starting AMT for chronic diseases after an
initial AM-related consultation of at least 30 min. The
study was conducted in conjunction with a health insur-
ance program reimbursing AM-related physician consul-
tations regardless of diagnosis. For this reason, and
because the range and frequency of indications for AMT in
primary care was largely unknown prior to the study, we
included patients of all ages with all diagnoses. Most fre-
quent indications were mental, respiratory, and muscu-
KITA Psychosoma and Daily Life subscales Figure 4
KITA Psychosoma and Daily Life subscales. Range 0–100, higher scores indicate better health. Children aged 1–7 years.
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KINDL Summary Score Figure 5
KINDL Summary Score. Range 0–100, higher scores indi-
cate better health. Children aged 8–16 years and German 
population sample (9–12 years) [31].
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loskeletal disorders. Following AMT, significant
improvements of disease symptoms and quality of life
were observed. The largest improvements (large effect
sizes, half of patients improved by at least 50% of their
baseline scores) were observed for the items which
directly measure the conditions treated with AMT, i.e. Dis-
ease and Symptom Scores. The improvements were main-
tained during the four-year follow-up and were not
accompanied by an increase of adjunctive therapies,
except for a small increase in psychotherapy use.
Strengths and limitations
Strengths of this study include a long follow-up period,
high follow-up rates, and the participation of 20% of all
AM-certified physicians in Germany. The participating
physicians resembled all eligible physicians with respect
to socio-demographic characteristics, and the included
patients resembled not included, screened patients
regarding baseline characteristics. These features suggest
that the study to a high degree mirrors contemporary AMT
practice. Moreover, in the present early phase of AMT eval-
uation, the inclusion of all diagnoses is an advantage,
offering a comprehensive picture of AMT practice. On the
other hand, it was not feasible to have disease-specific
outcomes for all diagnoses included. Nonetheless, the
larger AMOS project, of which this study is part, included
disease-specific outcomes for major disease groups
[35,36].
Since the study had a long recruitment period, the partic-
ipating physicians were not able to screen and include all
their eligible patients (patients starting AMT after pro-
longed AM-related consultations). The degree of selection
is not known for this part of the AMOS project, but for
other parts (patients referred to AM therapies) it was esti-
mated that physicians enrolled every fourth eligible
patient [35]. This selection could bias results if physicians
were able to predict therapy response and if they preferen-
tially screened and enrolled such patients for whom they
expected a particularly favourable outcome. In this case
one would expect the degree of selection (= the propor-
tion of eligible vs. enrolled patients) to correlate positively
with clinical outcomes. That was not the case, the correla-
tion was almost zero (-0.04). This analysis [35] does not
suggest that physicians' screening of eligible patients was
affected by selection bias.
A limitation of the study is the absence of a comparison
group receiving another treatment or no therapy. Accord-
ingly, for the observed improvements one has to consider
several other causes apart from AMT. Non-AM adjunctive
therapies cannot explain the improvement, since there
was comparable improvement in patients not using such
therapies (analysed in patients with mental, respiratory or
musculoskeletal disease or headache syndromes, together
comprising 50% of the study sample); the same applies to
adjunctive AM art and eurythmy therapy. Dropout bias
could explain up to 15% of the 0–12-month improve-
ment of Disease Score but only 4% of the corresponding
Symptom Score improvement. Natural recovery and
regression to the mean, which could also bias results, will
be addressed in a separate analysis (Hamre et al, submit-
ted for publication). Other possible confounders are
observation bias and psychological factors like patient
expectations. Since, however, AMT was evaluated as a
therapy package including physician-patient consulta-
tions, the question of specific therapy effects vs. non-spe-
cific effects (placebo effects, context effects, patient
expectations etc.) was not an issue of the present analysis.
Study implications
This study confirms previous studies of the characteristics
of AM users [10,37-40]: Patients are predominantly mid-
dle-aged women or children, education and occupation
levels are higher than average, and typical indications are
mental, respiratory, and musculoskeletal disorders. Previ-
ous studies of comprehensive AMT for chronic disease
have been conducted in inpatient settings (nine studies)
and outpatient clinics (four studies with range 18–54
patients [41-44]). The latter four studies showed:
improvement of symptoms and functional capacity and
decreased local and systemic inflammatory activity in
patients with inflammatory rheumatic disorders treated
largely without conventional antirheumatic medication
[41], successful epilepsy therapy without conventional
anticonvulsive drugs [42], high response rates in hepatitis
C patients treated without interferon [43], and decreased
asthma symptoms in children treated without glucocorti-
coids [44]. In accordance with these findings from sec-
ondary care, our predominantly primary care study
demonstrated long-standing improvements of disease
symptoms and quality of life in patients with mental, res-
piratory, and musculoskeletal diseases and other chronic
conditions.
In German general practice, a physician will spend an
average of 7½ minutes with each patient [1]. In this study,
physicians spent at least 30 minutes and provided AMT
(AM-related consultations and AM medication). Study
results show that these interventions can be associated
with favourable clinical outcomes.
Conclusion
In this study, patients treated by AM physicians after an
initial prolonged consultation had long-term reduction of
chronic disease symptoms and improvement of quality of
life. Although the pre-post design of the present study
does not allow for conclusions about comparative effec-
tiveness", study findings suggest that physician-providedBMC Complementary and Alternative Medicine 2007, 7:10 http://www.biomedcentral.com/1472-6882/7/10
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AM therapy may play a beneficial role in the long-term
care of patients with chronic diseases.
List of abbreviations
AM: anthroposophic medicine, AMOS: Anthroposophic
Medicine Outcomes Study, AMT: AM-related consulta-
tions with study physician + AM medication, IQR: inter-
quartile range.
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